| 查看: 793 | 回复: 16 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
英语翻译
|
|||
|
Dose response studies The Applicant has presented two phase 2 studies for the claimed indications (for cSSTI: Study 200 and for cIAI: Study 202). Study 200 was a randomized, open-label, comparison study of hospitalized subjects with complicated Skin and Soft Tissue infections in which 160 patients received either tigecycline 25 or 50 mg twice daily with an initial dose of 50 or 100 mg, respectively. The clinical data from this study indicated a trend toward a dose-related clinical cure response (67% and 74%, respectively) and dose-related pathogen eradication (56% and 70%). Also dose-safety relationships appeared evident for the adverse events (AEs) of nausea (22% and 35%) and vomiting (13% and 18%). Since tigecycline is intended for use in complicated infections, efficacy was favoured in benefit/risk -balance, and the greater dosage schedule (50 mg twice daily with an initial dose of 100 mg) was used in all consecutive clinical Phase II and III trials. Study 202 was a phase 2, multicenter, open-label study in hospitalized subjects with complicated intra-abdominal infections in which 111 subjects received an initial IV loading dose of 100 mg of tigecycline followed by 50 mg every 12 hours. Treatment continued for at least 5 days but not more than 14 days. There were no comparator or placebo groups. Overall, it appears that the choice of the dosage regimen for phase 3 studies is based on pharmacokinetic considerations as well as tolerability. The safety profile in these phase 2 studies is consistent with that seen in the larger database of phase 3 clinical trials. However, it should be highlighted that one case of Clostridium difficile associated colitis has been reported in Study 202. Apparently, this was the only one serious case reported of this adverse event for subjects in Phase 2 and 3 trials. Complicated intra-abdominal infections (cIAI) Methods Two pivotal phase 3 trials (studies 301 and 306) have been submitted in support of the indication complicated intra-abdominal infections. Study 301 was carried out in the Western hemisphere, and 306 in worldwide. The study protocols were similar in all essential points. Both phase 3 were multicenter, double-blind (third-party unblinded) studies in which 1568 hospitalised patients (approximately 800 patients per trial) with complicated intra-abdominal infections who were candidates for or had received a laparotomy, laparoscopy, or percutaneous drainage of an intraabdominal abscess were randomized. Key inclusion criteria were the followings: 1. Hospitalized male or female subjects, at least 18 years of age. 2. Candidate for, or had, a laparotomy, laparoscopy, or percutaneous drainage of an intra-abdominal abscess. 3. Complicated intra-abdominal infection, such as: a. An intra-abdominal abscess. b. An intra-abdominal abscess (including liver and spleen) that developed in a postoperative subject who received more than 48 hours but not more than 5 days of a nonstudy antibiotic and an intraabdominal culture was obtained from the infected site. c. Appendicitis complicated by perforation (grossly visible) and abscess or periappendicular abscess. d. Perforated diverticulitis complicated by abscess formation or faecal contamination. e. Complicated cholecystitis with evidence of perforation or empyema. f. Perforation of the large or small intestine with abscess or fecal contamination. g. Purulent peritonitis or peritonitis associated with faecal contamination. h. Gastric or duodenal ulcer perforation with symptoms lasting at least 24 hours before operation. i. Traumatic bowel perforation with symptoms lasting at least 12 hours before operation. 4. No more than 1 dose of an antibiotic (single broad-spectrum agent or 1 dose of each antibiotic in a combination regimen such as metronidazole, ampicillin,gentamicin) after the baseline intra-abdominal culture was obtained from the infected site. [ Last edited by 痴夷子皮 on 2011-1-10 at 13:07 ] |
回复此楼» 猜你喜欢
26药学专硕105500求调剂
已经有8人回复
-
297，工科调剂?
已经有11人回复
-
申博自荐
已经有4人回复
-
294求调剂
已经有9人回复
-
289 分105500药学专硕求调剂(找B区学校)
已经有5人回复
-
291求调剂
已经有11人回复
-
304求调剂
已经有8人回复
-
求调剂推荐
已经有9人回复
-
求调剂
已经有12人回复
-
291求调剂
已经有13人回复
» 抢金币啦！回帖就可以得到:
-
万人领军
+3/92
-
考研落榜生看过来
+1/87
-
重庆大学刘坤教授课题组招聘等离子体农业应用相关方向科研助理（农学、等离子体、电子
+1/80
-
长江大学化工学院化工学硕、专硕最后一批调剂（理学、工学均可）
+1/80
-
工学门类（前两位代码08）满足国家考研A区工科门类分数线要求的同学看过来
+1/49
-
盐城师范学院生物与医药（生物技术与工程领域）还有调剂名额
+1/36
-
生物与医药（生物技术与工程领域）调剂还剩最后一小时，请抓紧时间，
+1/34
-
硕士招生
+1/34
-
大家好，请教个问题，连续挤出胶皮，有没有在线降低气味VOC的方式。
+1/19
-
岭南师范学院化学化工学院生物与医药制药工程专业需要大量调剂生
+1/15
-
上海交通大学材料成形（塑性加工）常年招聘硕士研究生、博士研究生和博士后
+1/9
-
招材料相关专业调剂生
+1/9
-
AIRS微纳机器人中心诚招研究型硕士生（Mphil）、全职科研助理（RA）、实习生（Intern�
+1/8
-
重庆三峡科技大学电磁场与微波技术专业接收调剂，考数二可调，系统4月13日开放
+1/5
-
华南师范大学环境学院大分子体系多尺度模拟与实验研究团队招收2026年考研调剂生1名
+1/5
-
求英文文献
+1/3
-
南京大学FinTech大模型实验室招募斯坦福国际联培博士生和博士后及科研助理
+1/2
-
山东科技大学×中国地质调查局成都地质调查中心招收2026级硕士联培生
+1/2
-
抗病毒性传染病创新药物全国重点实验室—生物与医药还有3个指标，可跨专业调剂
+1/1
-
【招生or调剂-微纳光学】西部某重本高校，小众但扎实的课题组
+1/1
12楼2011-01-12 11:08:53
5楼2011-01-10 13:31:48
6楼2011-01-10 13:37:57
7楼2011-01-10 13:40:17
